Growth factor expression and effects of amrinone in monocrotaline- induced pulmonary hypertension in rats

Biochemical and Molecular Medicine

Volumn 58, Issue 2, 1996, Pages 204-210

  Burch, Grant H ^a,b   Jensen, Lloyd R ^a   Pappas, Jeanette ^a   Hammond, Elizabeth H ^a   Banner Jr , William ^a,c   Shaddy, Robert E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Saint Francis Hospital Tulsa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; GROWTH FACTOR; MONOCROTALINE; PHOSPHODIESTERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; VASODILATOR AGENT; VERAPAMIL;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTERY WALL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; LUNG WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PULMONARY HYPERTENSION; RAT; VASODILATATION;

ANIMALIA;

EID: 0030220570     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1996.0050     Document Type: Article

References (34)

1. 1. Salomon RN, Hughes CCW, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Am J Pathol 138:791-798, 1991.
2. 2. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129-1132, 1991.
3. 3. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 68:106-113, 1991.
4. 4. Shaddy RE, Hammond EH, Yowell RL. Growth factor expression in cardiac biopsy and autopsy specimens of heart transplant patients. Am J Cardiol 77:1210-1215, 1996.
5. 5. Shaddy RE, Ajer S, Chan S, Bishop DK. Growth factor expression in the mouse heterotopic heart transplantation model. Pediatr Res 35:41A, 1994. [Abstract].
6. 6. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 24:H1484-H1491, 1988.
7. 7. Todorovich-Hunter L, Johnson DJ, Ranger P, Keeley FW, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. Lab Invest 58:1841-1895, 1988.
8. 8. Ilkiw R, Todorovich-Hunter L, Maruyama K, Shin J, Rabinovitch M. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats. Circ Res 64:814-825, 1989.
9. 9. Ye CL, Rabinovitch M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol 261:H1255-1267, 1991.
10. 10. Todorovich-Hunter L, Dodo H, Ye C, McCready L, Keeley FW, Rabinovitch M. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis 146:213-223, 1992.
11. 11. Olson JW, Altiere RJ, Gillespie MN. Prolonged activation of rat lung ornithine decarboxylase in monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 3:3633-3637, 1984.
12. 12. Olson JW, Orlinska U, Gillsepie MN. Polyamine synthesis blockade in monocrotaline-induced pneumotoxicity. Biochem Pharmacol 38:2903-2910, 1989.
13. 13. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 71:2483-2492, 1991.
14. 14. Ono S, Voelkel NF. PAF receptor blockade inhibits lung vascular changes in the rat monocrotaline model. Lung 170:31-40, 1992.
15. 15. Gillespie MN, Rippetoe PE, Haven CA, Shiao RT, Orlinska U, Maley BE, Olson JW. Polyamines and epidermal growth factor in monocrotaline-induced pulmonary hypertension. Am Rev Respir Dis 140:1463-1466, 1989.
16. 16. Katayose D, Ohe M, Yamauchi K, Ogata M, Shirato K, Fujita H, Shibahara S, Takishima T. Increased expression of PDGF A-and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 264:L100-L106, 1993.
17. 17. Ross RR, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 46:155-169, 1986.
18. 18. Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol 139:570-579, 1989.
19. 19. McNeil PL, Muthukrishnare L, Warder E, D'Amore PA. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 109:811-822, 1989.
20. 20. Mathew R, Guzowski DE, Gloster ES. Effect of verapamil on monocrotaline-induced pulmonary artery hypertension and endothelial dysfunction in rats. Exp Lung Res 16:627-644, 1990.
21. 21. Shaddy RE, Paisley JE, Hansen JC. Amrinone inhibits thrombin-induced platelet-derived growth factor-like protein secretion from endothelial cells. Pediatr Res 30:351-354, 1991.
22. 22. Shubat PJ, Banner W, Huxtable RJ. Pulmonary vascular responses induced by the pyrrolizidine alkaloid, monocrotaline, in rats. Toxicon 25:995-1002, 1987.
23. 23. Reilly TM, Taylor DS, Herblin WF, Thoolen MJ, Chiu AT, Watson DW, Timmermans PB. Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem Biophysic Res Commun 164:736-743, 1989.
24. 24. Kullberg MP, Dorrbecker B, Lennon J, Rowe E, Edelson J. High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivatives in plasma. J Chromatogr 187:264-270, 1980.
25. 25. Han RN, Mawdsley C, Souza P, Tanswell AK, Post M. Platelet-derived growth factor and growth-related genes in rat lung. III. Immunolocalization during lung development. Pediatr Res 31:323-329, 1992.
26. 26. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 46:1086-1091, 1993.
27. 27. Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA. Pulmonary hypertension due to monocrotaline pyrrole is reduced by thrombocytopenia. Am J Physiol 255:H1165-H1172, 1988.
28. 28. Melan MA, Sluder G. Redistribution and differential extraction of soluble proteins in permeabilized cultured cells. J Cell Sci 101:731-743, 1992.
29. 29. Hughes SE, Hall PA. Immunolocalization of fibroblast growth factor receptor 1 and its ligands in human tissues. Lab Invest 69:173-182, 1993.
30. 30. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 137:85-92, 1990.
31. 31. Cordon-Cardo C, Vlodavsky I, Haimovitz-Friedman A, Hicklin D, Fuks Z. Expression of basic fibroblast growth factor in normal human tissues. Lab Invest 63:832-839, 1990.
32. 32. Gonzalez A-M, Buscaglia M, Ong M, Baird A. Distribution of basic fibroblast growth factor in the 18-day rat fetus: Localization in the basement membranes of diverse tissues. J Cell Biol 110:753-765, 1990.
33. 33. Powell PP, Klagsbrun M, Abraham JA, Jones RC. Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension. Am J Pathol 143:784-793, 1993.
34. 34. Perkett EA. Role of growth factors in lung repair and disease. Curr Opin Pediatr 7:242-249, 1995.